Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1148375 | 0.73 | MCL1 (0.35) | ABCG2KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL18472173 | 0.68 | ABCG2 (0.43) | ABCG2MEN1MAPTKMT2A | |
| SCHEMBL6316182 | 0.68 | HSD17B10 (0.46) | ABCG2KDM4EMEN1ALDH1A1POLB | |
| SCHEMBL29463989 | 0.68 | HSD17B10 (0.46) | ABCG2KDM4EMEN1ALDH1A1POLB | |
| SCHEMBL18718011 | 0.65 | GPR84 (0.44) | ABCG2KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL20480431 | 0.65 | MCL1 (0.42) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL18717983 | 0.64 | GPR84 (0.43) | ABCG2KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL19080106 | 0.63 | CYP1A1 (0.41) | ABCG2 | |
| SCHEMBL12037338 | 0.63 | GSTP1 (0.41) | ABCG2KDM4EMEN1ALDH1A1ESR1 | |
| SCHEMBL9889871 | 0.63 | PGR (0.42) | ABCG2KDM4EMEN1ALDH1A1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084834-B2 | Chiral phosphoramidimidates and derivatives thereof | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2021-08-10 | — | — | US | disclosed |
| US-20180339999-A1 | CHIRAL PHOSPHORAMIDIMIDATES AND DERIVATIVES THEREOF | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2018-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180339999-A1 | CHIRAL PHOSPHORAMIDIMIDATES AND DERIVATIVES THEREOF | PLCB3, PIN1, PLCD1 | ABCG2 2516/4885KDM4E 4152/4885MEN1 1591/4885 |
| US-11084834-B2 | Chiral phosphoramidimidates and derivatives thereof | PLCB3, PIN1, PLCD1 | ABCG2 2516/4885KDM4E 4152/4885MEN1 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.